MULTI-INSTITUTIONAL COOPERATIVE AGREEMENTS FOR CLINICAL EVALUATION OFMAGNETIC RESONANCE IMAGING IN BREAST CANCER - ADDENDUM

 

NIH GUIDE, Volume 25, Number 15, May 10, 1996

 

RFA:  CA-96-012

 

P.T. 34



Keywords:

  0715036 

  Medical/Diagnostic Imaging 

  Instrumentation, Medical 

 

National Cancer Institute

 

The National Cancer Institute (NCI) announces the following addendum

to the Request for Applications (RFA) CA-96-012 entitled "Multi-

Institutional Cooperative Agreements for Clinical Evaluation of

Magnetic Resonance Imaging in Breast Cancer," which appeared in the

NIH Guide for Grants and Contracts, Vol. 25, No. 12, April 19, 1996:

 

"Recent discoveries have made it clear that mutations in certain

genes, such as BRCA1 and BRCA2, can define a population of women

having increased genetic susceptibility for the development of breast

cancer.  The immanent commercial availability of genetic testing in

the near future heightens the need to evaluate the effectiveness of

new technologies such as breast MRI for the screening of women at

increased genetic risk, particularly since it is expected that many

women who are found to carry mutations will be in younger age groups,

where the sensitivity of conventional film mammographic screening is

problematic.  In addition to responding to the major focus of this

RFA, applicants anticipating access to meaningful numbers of patients

with mutations in known breast-cancer genes are strongly encouraged

also to propose pilot studies that evaluate the potential role of

breast MRI in detecting early breast cancer in women at increased

genetic risk."

 

To accommodate applicants who plan to incorporate MRI screening

studies of breast cancer in women at increased genetic risk into

their response to this RFA, applications also will be accepted on

August 27, 1996, in addition to the previously published receipt date

of July 30, 1996.

 

INQUIRIES

 

Questions regarding this addendum may be directed to:

 

Dr. Carl Mansfield

Division of Cancer Treatment, Diagnosis and Centers

National Cancer Institute

6130 Executive Boulevard, Suite 800 - MSC 7440

Bethesda, MD  20892-7440

Telephone:  (301) 496-6111

FAX:  (301) 480-5785

Email:  mansfieldc@dtpepn.nci.nih.gov

 

.

Return to 1996 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.